PSA and Prostate Monitoring on Testosterone: what to actually check

Current Endocrine Society and AUA guidance suggests checking PSA and performing a digital rectal exam before starting testosterone therapy, again at 3–12 months, and then annually in men over 40. The goal is to catch unexpected PSA velocity, not to rule testosterone in or out as a prostate cancer cause.

Men starting testosterone therapy almost always ask the same question in the first visit: is this going to give me prostate cancer? The short answer, based on more than a decade of accumulating data, is that testosterone therapy at physiologic doses does not appear to cause prostate cancer. The longer answer is that it can accelerate the growth of cancer that was already there — which is why PSA monitoring exists.

This post is about what that monitoring actually looks like on a real protocol: what to check before starting, what counts as a meaningful rise, and when a bump in PSA is noise versus a signal that deserves a urology referral.

Why PSA matters on TRT — in plain English

Prostate tissue is androgen-sensitive. When serum testosterone rises from a hypogonadal baseline back into the normal range, the prostate responds — usually with a small, early rise in PSA that stabilizes within the first 6–12 months. This is expected biology, not a complication.

The concern is different. If a man has a subclinical prostate cancer that was already present at baseline, restoring testosterone can make that cancer easier to detect, and in some cases accelerate its growth. The monitoring protocol is designed to catch that scenario early, not to prevent testosterone from reaching therapeutic levels.

A 2016 meta-analysis of exogenous and endogenous testosterone found no significant association between testosterone therapy and incident prostate cancer across pooled trials. The TRAVERSE trial, published in 2023, enrolled over 5,000 men with hypogonadism and cardiovascular risk and reported no significant difference in prostate cancer incidence between the testosterone and placebo arms over roughly 22 months of follow-up.

What to check before starting — the honest baseline

A thorough workup before testosterone therapy typically includes a baseline PSA and, in men over 40, a digital rectal exam (DRE). The Endocrine Society guideline recommends against starting testosterone in men with a PSA greater than 4 ng/mL — or greater than 3 ng/mL in men at increased risk of prostate cancer (African ancestry, first-degree relative with prostate cancer) — without a urology evaluation first.

The labs worth having before a serious testosterone protocol generally include:

• Total and free testosterone (two morning draws, fasting if possible)
• PSA
• Hematocrit (to establish a baseline before erythrocytosis risk)
• Estradiol, SHBG, LH, FSH
• Comprehensive metabolic panel and lipids

The PSA number alone is not the whole story. A single PSA of 2.8 in a 55-year-old with a stable prior value of 2.6 is different from a PSA of 2.8 that was 1.1 eighteen months ago. Trend matters more than the snapshot.

The core ruleA rise in PSA of more than 1.4 ng/mL in the first year of testosterone therapy, or a confirmed PSA above 4 ng/mL, is the Endocrine Society's threshold for urology referral — not a reason to panic, but a reason to look harder.

How often to recheck — the realistic cadence

Both the Endocrine Society (2018) and the AUA (2018) converge on a similar schedule:

• Baseline: PSA and DRE before starting (in men over 40, or younger with risk factors)
• 3–12 months after initiation: repeat PSA and DRE
• Annually thereafter: PSA and DRE in men over 40, as part of standard prostate health surveillance

Hematocrit follows a similar cadence (baseline, 3–6 months, then annually), because erythrocytosis is the other common lab-based reason to adjust a testosterone protocol.

If you choose to do bloodwork through us, these are the markers a clinician would typically look at first — alongside symptoms, cardiovascular history, and any lower urinary tract symptoms (LUTS) you're reporting.

What counts as a real PSA signal — versus noise

PSA is a noisy marker. It can fluctuate with recent ejaculation, cycling, prostatitis, a recent DRE, or urinary tract infection. The guidelines don't ask clinicians to react to any single value — they ask for confirmation.

The signals that warrant a urology referral, per the Endocrine Society:

• A confirmed PSA increase greater than 1.4 ng/mL within any 12-month period on testosterone
• A PSA velocity greater than 0.4 ng/mL/year, after the first six months, using the baseline on-treatment PSA
• A confirmed PSA above 4 ng/mL
• A new prostate abnormality on DRE
• A worsening of LUTS to an AUA symptom score above 19

A single spike that resolves on recheck 4–6 weeks later, with no infection or recent instrumentation, is usually noise. A sustained upward trend across two draws is the pattern that matters.

The goal of PSA monitoring on testosterone therapy is not to prove testosterone is safe. It is to catch the small number of men whose prostate biology changes meaningfully, early enough that a urologist has options.

What the data actually shows — and what it doesn't

The Registry of Hypogonadism in Men (RHYME), a prospective multinational registry, followed men on testosterone therapy and found no significant worsening of lower urinary tract symptoms and no increase in prostate cancer detection beyond what would be expected with routine PSA screening.

TRAVERSE, the largest randomized cardiovascular safety trial of testosterone to date, was not powered specifically for prostate cancer but reported low and comparable prostate cancer rates between arms (0.5% testosterone vs 0.4% placebo).

What the data does not yet show: long-term (10+ year) prostate outcomes in men who start testosterone in their 40s and stay on it. The current monitoring schedule is a reasonable hedge against that uncertainty, not a resolution of it. Men with a personal history of treated prostate cancer are a separate conversation and belong under urology co-management.

Putting it together

Testosterone therapy and prostate monitoring are not in tension. The monitoring is what makes long-term therapy defensible. A baseline PSA, a check at 3–12 months, and annual follow-up thereafter — paired with hematocrit, estradiol, and symptom tracking — is the structure that lets a clinician respond to a real signal when one appears, and ignore noise when it doesn't.

If your PSA has drifted and you're not sure whether it's meaningful, the next step is a confirmatory draw and a conversation about velocity, not a decision made from one number.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. Source
2. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. Source
3. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med. 2023;389(2):107-117. Source
4. Boyle P, Koechlin A, Bota M, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased PSA: a meta-analysis. BJU Int. 2016;118(5):731-741. Source
5. Debruyne FMJ, Behre HM, Roehrborn CG, et al. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int. 2017;119(2):216-224. Source

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.